Change search
ReferencesLink to record
Permanent link

Direct link
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
Quantify Res, SE-11221 Stockholm, Sweden..
Amgen Europe GmbH, Zug, Switzerland..
Amgen Europe GmbH, Zug, Switzerland..
Show others and affiliations
2015 (English)In: Osteoporosis International, ISSN 0937-941X, E-ISSN 1433-2965, Vol. 26, no 10, 2401-2411 p.Article in journal (Refereed) Published
Abstract [en]

The Summary The objectives of this study were to estimate persistence with denosumab and put these results in context by conducting a review of persistence with oral bisphosphonates. Persistence with denosumab was found to be higher than with oral bosphosphonates. Purpose This study had two objectives: to analyse persistence in Swedish women initiating denosumab for treatment of postmenopausal osteoporosis (PMO) and to put these findings in context by conducting a literature review and meta-analysis of persistence data for oral bisphosphonates. Methods The study used the Swedish Prescribed Drug Register and included women aged at least 50 years initiating denosumab between May 2010 and July 2012. One injection of denosumab was defined as 6-month persistence. Women were considered persistent for another 6 months if they filled their next prescription within 6 months + 56 days and survival analysis applied to the data. A literature search was conducted in PubMed to identify retrospective studies of persistence with oral bisphosphonates and pooled persistence estimates were calculated using a random-effects model. Results The study identified 2,315 women who were incident denosumab users. Mean age was 74 years and 61 % had been previously treated for PMO. At 12 and 24 months, persistence with denosumab was 83 % (95 % CI, 81-84 %) and 62 % (95 % CI, 60-65 %), respectively. The literature search identified 40 articles for inclusion in the meta-analysis. At 12 and 24 months, persistence with oral bisphosphonates ranged from 10 % to 78 % and from 16 % to 46 %, with pooled estimates of 45 % and 30 %, respectively. Conclusion These data from the Swedish Prescribed Drug Register and literature review suggest that persistence was higher with denosumab than with oral bisphosphonates.

Place, publisher, year, edition, pages
2015. Vol. 26, no 10, 2401-2411 p.
Keyword [en]
Bisphosphonates, Denosumab, Meta-analysis, Persistence, Retrospective, Review
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-264831DOI: 10.1007/s00198-015-3253-4ISI: 000361639700002PubMedID: 26282229OAI: diva2:861863
Available from: 2015-10-19 Created: 2015-10-19 Last updated: 2015-10-19Bibliographically approved

Open Access in DiVA

fulltext(778 kB)31 downloads
File information
File name FULLTEXT01.pdfFile size 778 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lundkvist, Jonas
In the same journal
Osteoporosis International
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 31 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 181 hits
ReferencesLink to record
Permanent link

Direct link